Journal of Cancer Research and Therapeutics Close
 

Figure 2: Tim-3 and PD-1 blockade could not increase the apoptosis of K562 target by NK cells in CLL patients. Magnetic-activated cell sorting-isolated NK cells from CLL patients (n = 18) were treated with human anti-Tim-3/anti-PD-1 (alone or combined) and isotype control antibodies. Cells were stimulated with IL-2 for 24 h and then co-cultured with K562 cell line as target (effector: target ratio 1:1). The population of K562 cells was initially gated and their apoptosis was determined by Annexin V/PI method using flow cytometry. (a) Flow cytometry dot plots represent the gating of K562 cells and the percentage of Annexin V/PI expressing K562 cells. (b) Apoptosis of K562 target by NK cells in all CLL patients. Graph represents the mean ± SD. Tim-3, CLL = Chronic lymphocytic leukemia, SD = Standard deviation, IL-2 = Interleukin-2, NK = Natural killer cell

Figure 2: Tim-3 and PD-1 blockade could not increase the apoptosis of K562 target by NK cells in CLL patients. Magnetic-activated cell sorting-isolated NK cells from CLL patients (<i>n</i> = 18) were treated with human anti-Tim-3/anti-PD-1 (alone or combined) and isotype control antibodies. Cells were stimulated with IL-2 for 24 h and then co-cultured with K562 cell line as target (effector: target ratio 1:1). The population of K562 cells was initially gated and their apoptosis was determined by Annexin V/PI method using flow cytometry. (a) Flow cytometry dot plots represent the gating of K562 cells and the percentage of Annexin V/PI expressing K562 cells. (b) Apoptosis of K562 target by NK cells in all CLL patients. Graph represents the mean ± SD. Tim-3, CLL = Chronic lymphocytic leukemia, SD = Standard deviation, IL-2 = Interleukin-2, NK = Natural killer cell